The role of statins in amyotrophic lateral sclerosis: protective or not?

Autor:	Al-Kuraishy HM; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Jabir MS; Department of Applied Sciences, University of Technology, Baghdad, Iraq., Sulaiman GM; Department of Applied Sciences, University of Technology, Baghdad, Iraq., Mohammed HA; Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim, Saudi Arabia.; Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt., Al-Gareeb AI; Department of Clinical Pharmacology and Medicine, College of Medicine, Jabir Ibn Hayyan Medical University, Kufa, Iraq., Albuhadily AK; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Jawad SF; Department of Pharmacy, Al-Mustaqbal University College, Hillah, Iraq., Swelum AA; Department of Animal Production, King Saud University, Riyadh, Saudi Arabia., Abomughaid MM; Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia.
Jazyk:	angličtina
Zdroj:	Frontiers in neuroscience [Front Neurosci] 2024 Jun 05; Vol. 18, pp. 1422912. Date of Electronic Publication: 2024 Jun 05 (Print Publication: 2024).
DOI:	10.3389/fnins.2024.1422912
Abstrakt:	Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of motor neurons characterized by muscle weakness, muscle twitching, and muscle wasting. ALS is regarded as the third-most frequent neurodegenerative disease, subsequent to Alzheimer's disease (AD) and Parkinson's disease (PD). The World Health Organization (WHO) in 2007 declared that prolonged use of statins may induce development of ALS-like syndrome and may increase ALS risk. Subsequently, different studies have implicated statins in the pathogenesis of ALS. In contrast, results from preclinical and clinical studies highlighted the protective role of statins against ALS neuropathology. Recently, meta-analyses and systematic reviews illustrated no association between long-term use of statins and ALS risk. These findings highlighted controversial points regarding the effects of statins on ALS pathogenesis and risk. The neuroprotective effects of statins against the development and progression of ALS may be mediated by regulating dyslipidemia and inflammatory changes. However, the mechanism for induction of ALS neuropathology by statins may be related to the dysregulation of liver X receptor signaling (LXR) signaling in the motor neurons and reduction of cholesterol, which has a neuroprotective effect against ALS neuropathology. Nevertheless, the exact role of statins on the pathogenesis of ALS was not fully elucidated. Therefore, this narrative review aims to discuss the role of statins in ALS neuropathology. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Al-kuraishy, Jabir, Sulaiman, Mohammed, Al-Gareeb, Albuhadily, Jawad, Swelum and Abomughaid.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu